Table 1:
Clinical and demographic characteristics of patients with and without clinical benefit from immune checkpoint blockade therapy
| Variables | Patients with clinical benefit n (%) | Patients with no clinical benefit n (%) |
|---|---|---|
| Total patients | 4 (25) | 12 (75) |
| Age at diagnosis, median (mean), range, YEARS | 50.5 (49.3), 34–62 | 51.5 (53.5), 38 – 69 |
| Stage at diagnosis | ||
| I | 0 | 2 (17) |
| II | 0 | 1 (8) |
| III | 3 (75) | 5 (42) |
| IV | 1 (25) | 4 (33) |
| Neoadjuvant chemotherapy | ||
| Yes | 2 (50) | 2 (17) |
| No | 2 (50) | 10 (83) |
| Surgery outcome | ||
| CGR | 0 | 5 (42) |
| OD | 2 (50) | 3 (25) |
| SD | 2 (50) | 1 (8) |
| Unknown | 0 | 2 (17) |
| No cytoreductive surgery | 0 | 1 (8) |
| ICB target | ||
| PD-1/PD-L1 | 1 (25) | 4 (33) |
| PD-1/PD-L1 + CTLA-4 | 3 (75) | 4 (33) |
| PD-1/PD-L1 + targeted therapy | 0 | 4 (33) |
| ICB duration, median (mean), range, DAYS | 383 (340), 21–574 | 51.5 (57.6), 14 – 153 |
| Discontinuation reason a | ||
| POD | 2 (50) | 12 (100) |
| Adverse event | 1 (25) | 1 (8) |
| Still on treatment | 1 (25) | 0 |
| TTF, median (mean), range, DAYS | 402 (776), 358–1568b | 76 (87), 27–167 |
| PFS, median (mean), range, DAYS | 387 (754), 336–1538b | 53 (70), 21 – 151 |
| Number of treatment lines | ||
| Prior to ICB | 3 (3.4), 1–7 | 3 (2.9), 1–7 |
| After ICB | 2 (1.6), 0–4 | 1 (1.2), 0–6 |
CGR: complete gross resection; OD: optimal debulking; SD: suboptimal debulking; ICB: immune checkpoint blockade; PD-1: programmed cell death protein 1; PD-L1: programmed death-ligand 1; CTLA-4: cytotoxic T-lymphocyte–associated antigen 4; POD: progression of disease; TTF: time to treatment failure; PFS: progression free survival
a
One patient discontinued treatment due to simultaneous POD and adverse event
b
Does not include TTF/PFS for Patient 10 and Patient 12, both of whom remain disease free and have not started next-line therapy at the time of data freeze, when censoring occurred.